Please assess the completion status of the following clinical trial:

Trial Title: Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age over 18 yrs~* consent obtained~* septic shock (according to international definition)~* patient sedated and submitted to invasive mechanical ventilation~* no need for surgery expected within 24 hours after enrollment~* patient has received at least one dose of large spectrum antibiotics~* superior vena cava catheter in place~* patient carrying a thermodilution device for cardiac output measurement~* stable mean arterial pressure within 65-5 mmHg limits for at least 2 hours;~Exclusion Criteria:~* pregnancy~* age below 18 years~* patient treated with iv continuous epinephrine~* chronic occlusive arteriopathy of the upper limbs~* regular or recent treatment with glibenclamide or glipizide~* regular or recent treatment with steroids~* known surrenal insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): 10 mL normal saline iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H8, H14 and H20
- hydrocortison (Type: ACTIVE_COMPARATOR): 50 mg hydrocortison iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H12, H18 and H24

Based on this trial design, predict the completion outcome and termination type (if applicable).